SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Destiny Tech100, Inc. operates as a non-diversified, closed-end management investment company. The company was founded on November 18, 2020 and is headquartered in Austin, TX.

Destiny Tech100 Inc

DESTINY TECH 100 INC

Destiny Tech100 is trending as investors aggressively rotate into the fund to gain exposure to high-profile private companies, specifically SpaceX and Anthropic, ahead of expected IPO activity. The community is actively debating the fund's premium over its Net Asset Value compared to alternative vehicles, while closely watching for a potential short squeeze driven by the stock's relatively low float.

DraftKings, Inc. is a digital sports entertainment and gaming company, which engages in the provision of online sports betting, online casino, daily fantasy sports product offerings, DraftKings Marketplace, retail sportsbook, media, and other consumer product offerings. The company was founded by Jason D. Robins, Matthew Kalish, and Paul Liberman on December 31, 2011 and is headquartered in Boston, MA.

DraftKings Inc. - Ordinary Shares - Class A

DraftKings Inc

DraftKings is facing intense investor scrutiny driven by legal challenges regarding NCAA trademarks and ongoing debates over the impact of emerging prediction market platforms. The community is sharply divided, with many actively loading up on short positions while others debate whether recent volatility represents a long-term accumulation opportunity.

Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which is engaged in the discovery and development of therapeutics for the treatment of rare diseases. The company was founded on July 22, 1980, and is headquartered in Cambridge, MA.

Sarepta Therapeutics Inc

Sarepta Therapeutics is experiencing a significant surge in momentum as investors react to promising early clinical trial data from its new siRNA pipeline targeting rare muscle disorders, FSHD1 and DM1. While the community is actively debating the potential for a short squeeze and long-term valuation recovery, there is focused excitement regarding the company's best-in-class delivery platform and the strategic pivot toward these new programs.

Celsius Holdings, Inc. engages in the development, marketing, sale, and distribution of functional drinks and liquid supplements. It also offers post-workout functional energy drinks and protein bars. The company was founded in April 2004 and is headquartered in Boca Raton, FL.

Celsius Holdings Inc

Celsius is facing significant downward pressure as investors speculate on potential market share loss following the launch of a private-label energy drink by Costco, though many in the community dismiss this as a temporary overreaction. The stock is currently marked by intense debate between those aggressively buying the dip, citing strong brand loyalty and long-term growth, and critics who are increasingly vocal about perceived mismanagement and concerns over declining momentum.

Polywhale

KRILL is gaining significant social momentum as participants compare it to recent ocean-themed tokens and speculate on potential breakout patterns. Community members are actively discussing the coin's price action and broader market trends, fueling discussions about its potential for rapid growth.

ADMA Biologics, Inc. operates as a biopharmaceutical company, which is engaged in manufacturing, marketing, and developing specialty plasma-derived biologics. The firm operates through the following business segments: ADMA BioManufacturing and Plasma Collection Center. The ADMA BioManufacturing segment consists of immune globulin manufacturing and development operations. The Plasma Collection Center consists of source plasma collection facilities. The company was founded by Adam S. Grossman and Jerrold B. Grossman on June 24, 2004 and is headquartered in Ramsey, NJ.

Adma Biologics Inc

ADMA is currently facing significant volatility and market scrutiny following a critical short report from Culper Research, which has sparked intense debate between investors defending the company's fundamentals and those concerned by the allegations of channel stuffing. While management has dismissed the report as inaccurate and speculative, shareholders are actively monitoring institutional responses and awaiting a formal rebuttal to provide the clarity needed to stabilize investor sentiment.

The Shrimp Army

SHRIMPS is gaining traction within speculative crypto circles as traders draw parallels to previous successful meme coin runners. Community sentiment is highly bullish, with active discussion focusing on the token's potential to mirror the performance of other whale-themed assets in the sector.

ORCASM is a filthy little memecoin that knows exactly what you came for. It launched on Orca's Wavebreak but was born to make waves—wet, loud, and unforgettable. This isn’t your ordinary meme. ORCASM builds up the tension slow, goes deep, and leaves you gasping for more. It’s raw, unfiltered trencher energy dripping with shameless satisfaction. No promises. No roadmaps. Just pure, orcasmic pleasure.

Orcasm

Orcasm is trending as part of a surge in marine-themed meme coins, with community members actively discussing its potential for rapid price movement and speculative growth. Investors are debating the project's viability, with many comparing it to other ocean-themed tokens and highlighting it as a high-risk, high-reward opportunity.

Moonlake Immunotherapeutics operates as a clinical-stage biotechnology company. It offers tri-specific Nanobody, Sonelokimab to address significant unmet needs in inflammatory skin and joint diseases. The company was founded by Kristian Reich, Jorge Santos da Silva, and Arnout Ploos van Amstel in 2021 and is headquartered in Zug, Switzerland.

MoonLake Immunotherapeutics - Ordinary Shares - Class A

MoonLake Immunotherapeutics

MoonLake Immunotherapeutics is trending as the community eagerly awaits long-term Week 40 trial data for Sonelokimab, which many view as a pivotal catalyst to validate its 'best-in-class' potential. Investors are actively debating the impact of upcoming conference presentations and ongoing M&A speculation, with high-conviction bulls emphasizing the strong institutional positioning and the potential for a paradigm shift in Hidradenitis Suppurativa treatment.

Navan, Inc. engages in offering a cloud-based technology platform for travelers. Its products include business travel and expense management. The company was founded by Ariel Cohen and Ilan Twig in February 2015 and is headquartered in Palo Alto, CA.

Navan Inc. - Ordinary Shares - Class A

Navan shares are seeing significant volatility as investors digest a strong earnings report featuring impressive revenue growth and margin expansion, alongside ongoing debates regarding the company's valuation and long-term path to profitability. While the community remains divided over the stock's recent performance, discussions are heavily focused on its AI-driven enterprise platform, insider buying activity, and the potential impact of its recent inclusion in major market indices.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

UBS Group Cuts Kayne Anderson BDC (NYSE:KBDC) Price Target to $14.50

UBS Group cut their price target on shares of Kayne Anderson BDC from $15.00 to $14.50 and set a "neutral" rating on the stock in a report on Friday...

All You Need to Know About Kayne Anderson BDC, Inc. (KBDC) Rating Upgrade to Buy

Kayne Anderson BDC, Inc. (KBDC) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Insider Buying: Kayne Anderson BDC (NYSE:KBDC) Director Acquires 9,000 Shares of Stock

Kayne Anderson BDC, Inc. (NYSE:KBDC - Get Free Report) Director George Marucci, Jr. bought 9,000 shares of the company's stock in a transaction that occurred on Friday, March 6th. The stock was...

Kayne Anderson BDC (NYSE:KBDC) Director George Marucci Jr Purchases 9,000 Shares

Kayne Anderson BDC, Inc. (NYSE:KBDC - Get Free Report) Director George Marucci, Jr. purchased 9,000 shares of the company's stock in a transaction on Friday, March 6th. The stock was bought at an...

Kayne Anderson BDC (NYSE:KBDC) Director George Marucci Jr Purchases 1,000 Shares

Kayne Anderson BDC, Inc. (NYSE:KBDC - Get Free Report) Director George Marucci, Jr. acquired 1,000 shares of the company's stock in a transaction dated Wednesday, March 4th. The shares were purchased...

Kayne Anderson BDC (NYSE:KBDC) Given New $14.00 Price Target at Wells Fargo & Company

Wells Fargo & Company lowered their price objective on Kayne Anderson BDC from $15.00 to $14.00 and set an "overweight" rating for the company in a research note on Wednesday...

Keefe, Bruyette & Woods Has Lowered Expectations for Kayne Anderson BDC (NYSE:KBDC) Stock Price

Keefe, Bruyette & Woods cut their target price on Kayne Anderson BDC from $16.00 to $15.50 and set an "outperform" rating on the stock in a research report on Wednesday...

Kayne Anderson BDC, Inc. (NYSE:KBDC) Short Interest Update

Kayne Anderson BDC, Inc. (NYSE:KBDC - Get Free Report) was the target of a large increase in short interest in the month of February. As of February 13th, there was short interest totaling 506,873...

Kayne Anderson BDC (NYSE:KBDC) Issues Earnings Results, Misses Expectations By $0.09 EPS

Kayne Anderson BDC (NYSE:KBDC - Get Free Report) posted its quarterly earnings data on Monday. The company reported $0.32 EPS for the quarter, missing analysts' consensus estimates of $0.41 by...

Kayne Anderson BDC, Inc. Announces December 31, 2025 Financial Results and Declares First Quarter 2026 Dividend of $0.40 Per Share

Kayne Anderson BDC, Inc. (NYSE: KBDC) (KBDC or the Company), a business development company externally managed by its investment adviser, KA Credit Advisors, LLC, today announced its financial...

Kayne Anderson BDC, Inc, an evergreen fund, invests in middle market companies located in the United States with an EBITDA of USD 10 - 150 million. The fund focuses on a broad range of sectors and industries. It provides financing in the form of senior secured loans and split-lien loans to buyout transactions.

KBDC
Kayne Anderson BDC Inc

Feed

News

Sentiment

Fundamentals

Info

Latest KBDC News

KBDCKayne Anderson BDC Inc